James Stone
Clinical Senior Lecturer in Psychiatry and Honorary Consultant Psychiatrist
Data updated
Research Footprint
James Stone appears in 5 tracked papers (2012–2020), most studied alongside Psilocybin, Ketamine and Esketamine, across Schizophrenia, Neuroimaging & Brain Measures and Healthy Volunteers.
Most-cited paper: Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (1178 citations).
Frequent co-authors: Robin Carhart-Harris, David Nutt and David Erritzoe.
Background & Research
James M. Stone is a psychiatrist and researcher associated with psychosis and neuroimaging work at King's College London and related clinical/research settings. His publications span schizophrenia models, ketamine and psilocybin, and brain connectivity measures relevant to psychosis and psychedelic states. He has co-authored influential papers on how psychedelic drugs may inform understanding of psychosis and psychiatric mechanisms.
Key Impact
He is a psychosis and neuroimaging researcher whose work links drug models of schizophrenia with psychedelic and ketamine studies, including psilocybin fMRI and connectivity research.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations James Stone is associated with.
King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →South London and Maudsley NHS Foundation Trust
South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.
View stakeholder →Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →